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Objectives. This study sought to evaluate the cost-effectiveness
of primary angioplasty for acute myocardial infarction under
varying assumptions about effectiveness, existing facilities and
staffing and volume of services.
Background. Primary angioplasty for acute myocardial infarc-
tion has reduced mortality in some studies, but its actual effec-
tiveness may vary, and most U.S. hospitals do not have cardiac
catheterization laboratories. Projections of cost-effectiveness in
various settings are needed for decisions about adoption.
Methods. We created a decision analytic model to compare
three policies: primary angioplasty, intravenous thrombolysis
and no intervention. Probabilities of health outcomes were taken
from randomized trials (base case efficacy assumptions) and
community-based studies (effectiveness assumptions). The base
case analysis assumed that a hospital with an existing laboratory
with night/weekend staffing coverage admitted 200 patients with a
myocardial infarction annually. In alternative scenarios, a new
laboratory was built, and its capacity for elective procedures was
either 1) needed or 2) redundant with existing laboratories.
Results. Under base case efficacy assumptions, primary angio-
plasty resulted in cost savings compared with thrombolysis and
had a cost of $12,000/quality-adjusted life-year (QALY) saved
compared with no intervention. In sensitivity analyses, when there
was an existing cardiac catheterization laboratory at a hospital
with >2200 patients with a myocardial infarction annually, pri-
mary angioplasty had a cost of <$30,000/QALY saved under a
wide range of assumptions. However, the cost/QALY saved in-
creased sharply under effectiveness assumptions when the hospi-
tal had <150 patients with a myocardial infarction annually or
when a redundant laboratory was built.
Conclusions. At hospitals with an existing cardiac catheteriza-
tion laboratory, primary angioplasty for acute myocardial infarc-
tion would be cost-effective relative to other medical interventions
under a wide range of assumptions. The procedure’s relative
cost-ineffectiveness at low volumes or redundant laboratories
supports regionalization of cardiac services in urban areas.
However, approaches to overcoming competitive barriers and
close monitoring of outcomes and costs will be needed.
(J Am Coll Cardiol 1997;30:1741–50)
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Recent randomized, controlled trials (1,2) have shown im-
proved outcomes after primary angioplasty compared with
intravenous thrombolysis for acute myocardial infarction. In
these research settings, primary angioplasty appeared no more
expensive than thrombolysis (3–5). However, the prospect of
providing primary angioplasty to general populations poses
several dilemmas.
If provided in the community, primary angioplasty may be
less beneficial than in research settings (6,7). Hospitals with
a lower volume of procedures have worse outcomes and
higher costs (8 –11). In addition, 80% of U.S. hospitals are
not equipped to provide primary angioplasty, and the costs
of the procedure would increase if new cardiac catheteriza-
tion laboratories needed to be built (12). Regionalization of
emergency services for chest pain might be one way of
directing patients to high volume hospitals, but any addi-
tional transit time needed could reduce the procedure’s
benefit (13).
Projections of cost-effectiveness under both efficacy and
effectiveness assumptions in a variety of settings are needed for
decisions about whether primary angioplasty should be
more widely adopted, and how services can be most effec-
tively organized. This study evaluated the cost-effectiveness
of primary angioplasty relative to thrombolysis and no
intervention for a hypothetical cohort of 10,000 patients
with acute myocardial infarction under a wide range of
assumptions about health outcomes, costs and hospital
characteristics.
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Methods
Model Structure
We developed a model to evaluate the health outcomes and
costs of primary angioplasty and intravenous thrombolytic
treatment of suspected acute myocardial infarction from the
societal perspective. The model (Fig. 1) was used to evaluate
three clinical policies for treating acute myocardial infarction:
primary angioplasty, thrombolysis and no intervention. No
intervention was defined as all patients receiving neither throm-
bolysis nor primary angioplasty but still admitted to the
hospital for standard care.
Patient subgroups. Patients were classified into four sub-
groups on the basis of clinical characteristics:
1. Cardiogenic shock—these patients were considered to al-
ways be eligible for primary angioplasty or thrombolysis.
2. Ineligible for intervention—other patients presenting .6 h
after the onset of symptoms, without $1 mm ST segment
elevation in two contiguous electrocardiographic leads, or
with complete left bundle branch block, were considered
ineligible for thrombolysis or primary angioplasty and
would have no intervention.
3. Bleeding risk factors—patients with specific risk factors for
bleeding, as defined by previous studies (14,15) would be
ineligible for thrombolysis but eligible for primary angio-
plasty.
4. Candidates for thrombolysis—the remaining patients were
considered eligible for either thrombolysis or primary an-
gioplasty.
Interventions. Primary angioplasty policy. Under the pri-
mary angioplasty policy, patients with cardiogenic shock, pa-
tients with bleeding risk factors and candidates for thrombol-
ysis all would undergo coronary arteriography. Those with
potentially treatable lesions would undergo attempted angio-
plasty without preceding intravenous or intracoronary throm-
bolytic treatment.
Thrombolysis policy. Under the thrombolysis policy, candi-
dates for thrombolysis would receive intravenous infusion of
either streptokinase or tissue-type plasminogen activator (t-
PA). The choice of intervention for the other patient sub-
groups would depend on whether the hospital had a cardiac
catheterization laboratory. At hospitals with an existing labo-
Figure 1. Decision tree illustrating possible clinical policies for a
hypothetical population of patients with an acute myocardial infarc-
tion. Squares 5 decision by the clinical policymaker; circles 5 chance
events not under the direct control. Under the No Intervention Policy,
all patients receive standard hospital treatment for acute myocardial
infarction, including heparin and aspirin. Under the Thrombolysis
Policy, those patients who are candidates for thrombolysis receive a
thrombolytic agent and standard care; those in cardiogenic shock
undergo either attempted angioplasty or receive thrombolysis, fol-
lowed by transport, if possible. Under the Primary Angioplasty Policy,
all patients undergo attempted angioplasty, unless they are ineligible
because of a nonqualifying electrocardiogram or symptom duration
.6 h. *For a hospital without an existing cardiac catheterization
laboratory: 1) under the Primary Angioplasty Policy, a new laboratory
would be built; 2) under the Thrombolysis Policy, no new laboratory
would be built.
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CMIS 5 Cost Management Information
System
QALY 5 quality-adjusted life-year
t-PA 5 tissue-type plasminogen activator
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ratory, patients with cardiogenic shock or bleeding risk factors
were assumed to undergo primary angioplasty as the preferred
intervention when the admitting hospital had a cardiac cathe-
terization laboratory. At hospitals without an existing labora-
tory, patients with bleeding risk would receive no intervention,
and those with cardiogenic shock would receive thrombolysis.
When possible, patients with cardiogenic shock would be
transported to a neighboring hospital for primary angioplasty.
Because .50% of the U.S. population lives in metropolitan
areas, transport was assumed to be possible for 50% of patients
with cardiogenic shock (16).
Hospital characteristics. A base case hospital (“Fully Cov-
ered Lab” scenario) was defined as follows: It had an existing
cardiac catheterization laboratory that performed elective pro-
cedures during weekdays and had cardiovascular surgical
backup. Night call for two technical staff members was as-
sumed to be already covered. Primary angioplasty was assumed
to be offered 24 h/day, every day. We inferred from two
previous studies (17,18) that ;50% of all patients with a
myocardial infarction present to hospitals that treat at least 150
myocardial infarctions/year (17,18). Thus, the base case hospi-
tal was assumed to have 200 annual discharges for acute
myocardial infarction.
Data and Assumptions: Health Outcomes
Probabilities of health outcomes (Table 1) were derived
from a review of published reports (19), unpublished studies,
analyses of Kaiser Permanente data and an expert panel
conference. Seven cardiologists (see Acknowledgments) con-
vened in person to review evidence tables that summarized the
published reports about each assumption. To derive each final
base case estimate, a modified Delphi approach was used in
which each panelist submitted initial estimates, then reviewed
and adjusted results to reach as much consensus as possible.
The base case used efficacy assumptions about health out-
comes based on published randomized trials.
Table 1. Health Outcomes After Interventions for Acute Myocardial Infarction
Outcome








In-hospital mortality among patient subgroups
In cardiogenic shock 0.52 (0.71) 0.71 0.85 23–30
Ineligible for intervention NA NA 0.10 15, 54–57
With bleeding risk factors 0.12 (0.26) NA 0.26 31, 32
Thrombolysis candidates 0.04 (0.06) 0.06 0.08 1, 2, 36–38
Among thrombolysis candidates
Nonfatal disabling stroke 0.0015 0.005 0.002 1, 33, 37
Bleeding requiring transfusion 0.03 0.02 0.005 Expert panel*
1-yr survival rate 0.93 (0.92) 0.92 0.85 4, 14, 15, 35, 36, 38, 40, 58–63
1-yr reinfarction rate 0.10 (0.10) 0.10 0.05 38, 40, 59, 61, 64–66
5-yr survival rate 0.82 (0.82) 0.82 0.77 58, 61, 64, 67
Procedure rates 1, 4–6, 38
CABG during hospital stay 0.10 (0.12) 0.12 0.09
CABG during next year 0.09 (0.09) 0.09 0.10
Angioplasty during hospital stay 0.04 (0.05) 0.30 0.18
Angioplasty during next year 0.15 (0.15) 0.15 0.15
Average length of hospital stay for uncomplicated
myocardial infarction (days)†
3, 6
ICU 2.5 (2.5) 3 3.5
Telemetry unit 2 (2) 2.5 3
Medical ward 1.5 (1.5) 1.5 1.5
Total 6 (6) 7 8
Proportions in CCS classes at 1 yr among
candidates for thrombolysis
4
I 0.83 (0.68) 0.68 0.68
II 0.16 (0.25) 0.25 0.25
III or IV 0.01 (0.07) 0.07 0.07
*Seven cardiologists who convened for 1 day to review base case estimates and provide ranges for sensitivity analysis using a modified Delphi process (see
Acknowledgments). †Fifty percent of the days saved in the thrombolysis and primary angioplasty groups were assumed to be intensive care unit (ICU) days, and 50%
were assumed to be telemetry unit days; for patients with risk factors for bleeding or cardiogenic shock, primary angioplasty and thrombolysis were assumed to not save
any hospital days relative to no intervention. CCS 5 Canadian Cardiovascular Society; CABG 5 coronary artery bypass graft surgery; NA 5 not applicable (under the
primary angioplasty and thrombolysis policies, patients ineligible for intervention would have no intervention and would have an in-hospital mortality rate of 0.10; under
the thrombolysis policy, patients with bleeding risk would have no intervention and would have an in-hospital mortality rate of 0.26); Ref 5 reference.
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Patient subgroups. On the basis of published studies
(20,21) and a Kaiser Permanente analysis, we assumed that
among all patients with an acute myocardial infarction, 3%
presented in cardiogenic shock, 65% were ineligible for inter-
vention, and 6% had risk factors for bleeding. The remaining
26% were candidates for thrombolysis (eligible for either
thrombolysis or primary angioplasty).
The model took into account that the probability of myo-
cardial infarction among patients within 6 h of chest pain onset
and with ST segment was 95% (22). It was assumed that
patients without a myocardial infarction would incur treatment
costs but would not benefit from thrombolysis or primary
angioplasty.
Survival. In-hospital mortality rates (Table 1) were taken
from published studies and expert panel opinion (23–35).
Among candidates for thrombolysis, a published meta-analysis
and our expert panel suggested a 4% in-hospital mortality rate
after primary angioplasty and a 6% mortality rate after throm-
bolysis (1,2,36–39). For candidates for thrombolysis, 1-year
survival rates were based on randomized studies and a pub-
lished meta-analysis (4,36,40). It was assumed that survival
differences between primary angioplasty and thrombolysis
groups were markedly attenuated by 1 year and gone at 5 years.
For patients with cardiogenic shock (41) and bleeding risk,
long-term survival rates were assumed to be lower than those
of candidates for thrombolysis. Those who survived the hospi-
tal period were assumed to have the same life expectancy
whether they underwent primary angioplasty or received
thrombolysis. For the subgroup with bleeding risk factors,
there is no published evidence on long-term survival; they were
conservatively assigned a life expectancy equal to patients who
were ineligible for intervention. Life expectancy for each
subgroup was calculated by combining the appropriate survival
rates with estimates of long-term post-myocardial infarction
life expectancy from the Coronary Heart Disease Policy Model
(42).
Cardiac procedures and stroke. For candidates for throm-
bolysis who underwent primary angioplasty, rates of coronary
artery bypass graft surgery (CABG) and angioplasty during the
hospital period and the subsequent year were estimated from
published data (3,5). Rates of angioplasty and CABG during
the subsequent year were assumed to be equal between the
primary angioplasty and thrombolysis groups. The rate of
nonfatal disabling stroke after thrombolysis was based on the
largest available study (33).
Quality of life. The quality-adjusted life-year (QALY)
saved is a standard outcome measure in cost-effectiveness
analyses (43). It takes into account not only the mortality but
also the morbidity prevented by an intervention. Candidates
for thrombolysis were assumed to have better cardiac func-
tional status after primary angioplasty than after thrombolysis
on the basis of published information observed at 1 year after
the acute myocardial infarction (4) (Table 1). These health
states and their utilities were assumed to apply through the end
of life. Survivors with bleeding risk and with cardiogenic shock
were conservatively assumed to not derive any advantage in
cardiac quality of life after primary angioplasty, although they
derived some advantage from a lower rate of stroke.
Quality of life adjustments were made using utilities from
published patient preference studies; community weights for
these categories of health states are not available. For Cana-
dian Cardiovascular Society classes, utilities were 0.970 for
class I, 0.970 for class II and 0.875 for class III or IV (44). For
nonfatal disabling stroke, the utility was 0.10 (45).
Data and Assumptions: Costs
The analysis incorporated costs, including administrative
overhead, of the initial hospital period, major cardiac proce-
dures, reinfarction during the subsequent year and future
medical expenses through the end of life. We used direct
medical costs from the societal perspective in 1993 U.S.
dollars. Costs from other years were adjusted to 1993 dollars
using the medical component of the Consumer Price Index
(16).
Initial hospital period. Members of Northern California
Kaiser Permanente, a nonprofit health maintenance organiza-
tion, with an acute myocardial infarction in 1993 were identi-
fied using a standard algorithm for International Classification
of Diseases, 9th Revision (ICD-9) codes developed by the
California Office of Statewide Health Planning Development.
Patients with coronary artery bypass graft procedures were
identified using diagnosis-related group (DRG) codes. The
mean costs of hospital days in the intensive care unit, telemetry
unit and regular medical ward were analyzed for these patients
using Kaiser Permanente’s Cost Management Information
System (CMIS).
Using CMIS, length of stay was evaluated for patients
discharged in 1993 with a myocardial infarction (n 5 1,905,
mean 6.6 days), myocardial infarction with CABG (n 5 198,
mean 13 days) and CABG alone (n 5 372, mean 9.5 days). For
candidates for thrombolysis, projected lengths of hospital stay
were based on these data and on the expert panel’s consensus
(Table 1).
Cardiac procedures and reinfarction. The initial cost of
primary angioplasty was estimated using a previously described
model (11) that took into account four factors: 1) whether
cardiac catheterization laboratories already existed at a hospi-
tal; 2) whether the laboratory’s technical personnel were
already paid for night call; 3) how cardiovascular surgical
backup would be provided; 4) the hospital’s annual number of
discharges for myocardial infarction. Using the base case
hospital’s characteristics, the initial cost of a primary angio-
plasty procedure was $2,068, including physician costs.
The cost of an elective angioplasty procedure was calcu-
lated by adding the costs of cardiologist time, supplies, wages
for technical and clerical personnel and cardiac catheterization
laboratory maintenance and depreciation. Elective angioplasty
was assumed to require a hospital admission of 2 days.
Reinfarction in the subsequent year was assumed to require a
hospital admission of 7 days.
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Other costs. The base case used the cost of t-PA for
thrombolysis (Table 2). Treatment for bleeding complications
was assumed to include transfusion of 2 U of packed red cells
and two additional days in the cardiac care unit (46). The costs
of nonfatal disabling stroke were based on Kaiser Permanente
CMIS data and on estimates from the National Nursing Home
Survey (47,48). The estimated annual average cost of medical
care from the 1-year anniversary of the myocardial infarction
to the end of life (Table 2) was calculated on the basis of
published estimates from the National Medical Expenditure
Survey (49) and the Coronary Heart Disease Policy Model
(18).
Outcome Measures
An Excel spreadsheet was used to calculate health out-
comes, costs and cost-effectiveness ratios from the societal
perspective for a hypothetical cohort of 10,000 patients admit-
ted to the hospital with an acute myocardial infarction. This
cohort included 1,000 patients/year for 10 years. Results were
expressed in net present value averaged over the 10-year
period. In the base case, per current recommendations, future
costs and life-years to the end of each patient’s life were
discounted at 3%/year (43).
Incremental cost-effectiveness ratios were defined as the
additional cost per additional health benefit of primary angio-
plasty compared with thrombolysis and of thrombolysis com-
pared with no intervention. Primary angioplasty was defined as
having dominance when it was both more effective and cost
saving than thrombolysis and having extended dominance
when its incremental cost effectiveness ratio was lower than
that of thrombolysis. When dominance or extended dominance
existed, it was appropriate to calculate the cost-effectiveness of
primary angioplasty compared with no intervention (43).
Sensitivity Analyses
Uncertainty surrounds the assumptions in every decision
analysis. We varied four major factors both individually and
simultaneously, as follows: 1) the effectiveness of primary
angioplasty; 2) the hospital scenarios in which it might be
offered; 3) the volume of services; and 4) the time to treatment.
Sensitivity analyses were also conducted for individual assump-
tions, including in-hospital mortality, long-term survival, sub-
sequent cardiac quality of life, the cost of thrombolysis, the
cost of future medical care for survivors and the discount rate.
Effectiveness assumptions. The base case analysis used
efficacy assumptions about health outcomes from randomized,
controlled trials in optimal settings. We conducted an alterna-
tive analysis that used effectiveness assumptions from
community-based observational studies of primary angioplasty
and thrombolysis (6,7). In the effectiveness assumptions, pri-
mary angioplasty had no advantages over thrombolysis in
in-hospital mortality or future survival for any of the patient
subgroups. It was also assumed the primary angioplasty and
thrombolysis groups had identical rates of CABG during the
initial hospital period and rates of CABG and elective angio-
plasty during the next 12 months. The only advantages that
primary angioplasty retained over thrombolysis were a shorter
hospital stay and lower rates of nonfatal disabling stroke and
bleeding requiring transfusion. When the volume of annual
myocardial infarctions was varied, assumptions about health
outcomes were changed only when explicitly stated.
Hospital scenarios. The initial cost of primary angioplasty
was varied on the basis of 10 alternative sets of assumptions
about the admitting hospital, as previously described; three are
presented here (11). The “Add Night Call” scenario was
identical to the base case hospital (“Fully Covered Lab”
scenario), except that night call for two technical staff members
was a new expense.
The “Add Needed Lab” scenario assumed that the admit-
ting hospitals were in a geographic area where there had been
elective procedures going unperformed for want of a cardiac
catheterization laboratory. Thus, part of the new laboratories’
costs were apportioned to 100 elective angioplasty and 700
Table 2. Costs Used in Analysis of Interventions for Acute
Myocardial Infarction
Service Cost (U.S. 1993 $)
Ref No. or
Other Source
ICU day 1,845 CMIS*
Telemetry unit day 955 CMIS*
Medical ward day 700 CMIS*
CABG procedure† 9,160 KP‡
Elective angioplasty procedure† 2,068 KP‡




Transport to neighboring hospital 500 KP**
Transfusion (2 U of packed RBCs) 225 KP**
Nonfatal disabling stroke
Initial rehabilitation 21,216 CMIS*
Outpatient physical therapy 1,248 CMIS*
Future nursing home care (400
days)
34,232 47, 48
Average annual medical costs from
1-yr anniversary of MI to end of
life
11,133 18, 49
*Estimate is from analysis of cases in Cost Management Information System
(CMIS) of Northern California Kaiser Permanente. †Professional time and
procedure costs (e.g., operating room, cardiac catheterization laboratory and
supplies) only; estimate includes overhead but does not include costs of hospital
stay; the cost of a coronary artery bypass graft surgery (CABG) procedure was
estimated on the basis of cardiovascular surgeons’ and anesthesiologists’ time
allocated for each procedure and the cost of cardiovascular operating room time,
which included technical personnel, room and equipment costs; after including
hospital costs, the total costs of an elective bypass surgery procedure would be
$23,000. ‡Estimate is based on analyses of Kaiser Permanente (KP) administra-
tive data. §Base case analysis estimate of $2,068 assumed an existing cardiac
catheterization laboratory and cardiovascular surgical backup; night call for
technical staff would be already covered, and the hospital would discharge 200
patients with myocardial infarction (MI)/year; costs under alternative scenarios
were $4,453 in the “Add Night Call” scenario, $5,140 in the “Add Needed Lab”
Scenario and $9,393 in the “Add Redundant Lab” scenario. RBCs 5 red blood
cells; t-PA 5 tissue-type plasminogen activator; other abbreviations as in Table 1.
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elective angiography procedures per year. In contrast, in
Northern California and many other urban areas, excess
capacity for elective angioplasty and angiography already
exists. For this reason, the “Add Redundant Lab” scenario
assumed that the economic cost of building and equipping the
new laboratories was attributable entirely to primary angio-
plasty. When a new laboratory was built, it was assumed that
cardiovascular surgical backup would be provided by transport
to a neighboring hospital.
Time to intervention. If primary angioplasty services were
regionalized, there might be delays in intervention due to
either increased travel time by emergency medical services or
time required for transfer if the patient initially presented to a
hospital without primary angioplasty. Data from the Global
Utilization of Streptokinase and Tissue Plasminogen Activator
for Occluded Coronary Arteries (GUSTO) (50) trial were used
to estimate the proportions of candidates for thrombolysis
ready for intervention at 0 to 2 h (20%), 2 to 4 h (50%) and 4
to 6 h (30%) after symptom onset. The absolute decrease in
benefit from a 1-h delay in reperfusion at 0 to 2 h (2%), 2 to 4 h
(0.5%) and 4 to 6 h (none) was nonlinear and was estimated
from a summary of recent thrombolysis trials (51). Combining
these data, we assumed that a 1-h delay in primary angioplasty
would result in an average 0.65% absolute increase in mortality
for candidates for thrombolysis. Only candidates for thrombol-
ysis who had undergone attempted angioplasty under the
primary angioplasty policy were assumed to have the 1-h delay;
those treated under the thrombolysis policy were assumed not
to have a delay.
Results
Health outcomes. For the hypothetical cohort of 10,000
patients with an acute myocardial infarction, under the base
case (efficacy) assumptions, primary angioplasty was predicted
to save 22% more lives and to reduce nonfatal disabling
strokes by one-third compared with thrombolysis (Table 3).
The improvement in survival was 741 undiscounted QALYs
(514 discounted QALYs) relative to thrombolysis.
Costs and cost-effectiveness. The primary angioplasty pol-
icy would save $7.2 million in short-term costs compared with
thrombolysis (Table 3). This was due to the primary angio-
plasty procedure’s slightly lower cost than that of t-PA and the
projected savings in hospital days. Even after the costs of
lifetime medical care for hospital survivors were included,
primary angioplasty would lead to cost savings of $1.9 million
relative to thrombolysis.
Primary angioplasty dominated thrombolysis because it had
both superior health outcomes and lower costs. In this situa-
tion, it was appropriate to express the cost/QALY saved by
primary angioplasty compared with no intervention, which was
$12,000.
Sensitivity analyses. Effectiveness assumptions and hospital
scenarios. For the base case hospital with an existing, fully
staffed laboratory, using effectiveness rather than efficacy as-
sumptions resulted in only a slight increase in the cost/QALY
saved by primary angioplasty, still $12,000. Likewise, primary
angioplasty continued to have a cost/QALY saved of ,$30,000
under alternative hospital scenarios, provided that efficacy
assumptions were used and the hospital’s annual volume of
myocardial infarctions was $200 (Fig. 2).
However, when effectiveness assumptions were combined
with alternative hospital scenarios, primary angioplasty ap-
peared much less cost-effective. Under effectiveness assump-
tions and at an annual volume of 200 myocardial infarctions,
the cost/QALY saved increased to $72,000 in the “Add
Needed Lab” scenario and to $330,000 in the “Add Redundant
Lab” scenario (Fig. 2).
Procedure volume. Under the “Add Night Call,” “Add
Needed Lab” and “Add Redundant Lab” scenarios, the cost/
QALY saved by primary angioplasty increased sharply as the
annual number of patients with an acute myocardial infarction
admitted to the hospital decreased (Fig. 2). When effectiveness
assumptions were used and the hospital admitted ,150 pa-
tients with a myocardial infarction/year, the cost/QALY saved
increased to .$100,000 in all hospital scenarios except the
base case hospital.
Time to intervention. Under base case efficacy assumptions,
increasing the time to intervention by 1 h reduced the undis-
counted QALYs saved by the primary angioplasty policy to
3,986 relative to no intervention (a 5% reduction) and 544
relative to thrombolysis (a 26% reduction). However, primary
angioplasty was still cost saving compared with thrombolysis
and had a cost/QALY saved of $12,000 compared with no
intervention. In contrast, under effectiveness assumptions,
increasing the time to intervention by 1 h resulted in higher
total mortality than thrombolysis, rendering this an ineffective
strategy no matter what the cost.
Other sensitivity analyses. For the base case hospital, the
“Add Night Call” scenario, and the “Add Needed Lab”
scenario, primary angioplasty always had a cost/QALY saved
of ,$20,000 when individual assumptions (e.g., in-hospital
mortality, long-term survival, subsequent cardiac quality of
life) were varied over plausible ranges. When the cost of
thrombolysis was changed to that of streptokinase ($320),
primary angioplasty’s cost/QALY was $7,000 compared with
thrombolysis, still less than that of thrombolysis compared with
no intervention. When future medical costs were not included,
the cost/QALY saved compared with no intervention ranged
from $400 for the base case hospital to $18,000 for the “Add
Redundant Lab” scenario. At a discount rate of 5% rather
than 3%, primary angioplasty still had projected cost savings
compared with thrombolysis and a cost of $12,000/QALY
saved compared with no intervention.
Discussion
Main findings. From a societal perspective, primary angio-
plasty for acute myocardial infarction would have reasonable
cost-effectiveness under a wide range of assumptions if pro-
vided by hospitals that already have fully supported cardiac
catheterization laboratories. Under base case assumptions, the
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procedure was projected to save costs compared with throm-
bolysis and to cost $12,000/QALY saved compared with no
intervention. The latter ratio is lower than those of many other
accepted medical interventions. These findings are in accord
with empirical studies (3–5) suggesting that the cost-
effectiveness of primary angioplasty under ideal conditions is
better than or equal to that of thrombolysis.
However, these results also underscore the potential cost-
ineffectiveness of primary angioplasty if provided in settings
where health outcomes are similar to those in observational
community-based studies and where the procedure’s costs are
higher or volumes are lower. Under effectiveness assumptions
and at low volumes, the cost/QALY saved under most hospital
scenarios rapidly increased beyond $100,000, out of the range
of most accepted medical interventions.
Policy implications. Our findings suggest that regionaliza-
tion of cardiac services would be desirable from a societal
perspective. Providing primary angioplasty cost-effectively will
depend on using existing cardiac catheterization laboratories
and maximizing hospitals’ volumes of procedures. Without
regionalization, the procedure might be offered by hospitals
with a lower volume or less experienced operators, which tends
to lead to worse angioplasty outcomes (6,8,10).
The present study was conducted to inform health policy
decisions rather than to direct individual bedside decisions.
The results suggest that primary angioplasty would have rea-
sonable cost-effectiveness if optimal costs and outcomes could
be achieved, even if the average time to intervention increased
by 1 h. In urban areas, where ;80% of the U.S. population
resides, regionalization might be achieved by having emer-
gency medical services triage symptomatic patients to high
volume hospitals with primary angioplasty capability.
In reality, the conflicting perspectives of the various stake-
holders in health care may pose a barrier to optimal use of
Table 3. Projected Outcomes of Primary Angioplasty and Thrombolysis Policies for a Hypothetical
Cohort of 10,000 Patients With Acute Myocardial Infarction
Clinical Policy
Primary
Angioplasty Thrombolysis No Intervention
Health outcomes
Deaths 982 1,034 1,269
Survivors 9,018 8,966 8,731
Nonfatal disabling strokes 16 25 17
Relative to no intervention
Lives saved 287 235 NA
Life-years saved (undiscounted) 4,310 3,626 NA
QALYs saved (undiscounted) 4,183 3,442 NA
Relative to thrombolysis
Lives saved 52 NA NA
Life-years saved (undiscounted) 684 NA NA
QALYs saved (undiscounted) 741 NA NA
Costs [U.S. $ in thousands (% of total costs)]*
Initial intervention 6,500 (1) 8,100 (1) NA
Initial hospital stay 102,000 (14) 107,000 (15) 108,000 (16)
Reinfarction and procedures in subsequent 12 mo 30,000 (4) 30,000 (4) 29,000 (4)
Subtotal for 12 mo 138,000 (19) 145,000 (20) 137,000 (20)
Future health costs of survivors 585,000 (81) 581,000 (80) 553,000 (80)
Total 724,000 (100) 726,000 (100) 690,000 (100)
Incremental 12-mo cost (savings)† (7,200) 8,300 NA
Incremental total cost† (1,900) 36,000 NA
Cost-effectiveness ratios‡
Vs. thrombolysis
$/life saved Savings NA NA
$/life-year saved Savings NA NA
$/QALY saved Savings NA NA
Vs. no intervention§
$/life saved 120,000 150,000 NA
$/life-year saved 11,000 14,000 NA
$/QALY saved 12,000 15,000 NA
*U.S. 1993 dollars, discounted at 3%/year over 10 years; numbers are rounded to two or three significant digits and
thus do not always add to total. †Incremental costs are primary angioplasty versus thrombolysis and thrombolysis versus
no intervention. ‡Costs and benefits discounted at 3%/year. §Primary angioplasty is considered economically preferable
to thrombolysis by the principle of extended dominance, because the cost/quality-adjusted life-year (QALY) saved of
primary angioplasty relative to thrombolysis is lower than that of thrombolysis relative to no intervention; thus, the
cost/QALY saved of primary angioplasty relative to no intervention is given. NA 5 not applicable.
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primary angioplasty. In the United States, decisions about
health services are usually made at the level of the individual
hospital or health plan, and this poses competitive barriers to
regionalization. An individual hospital in a competitive market
may seek to maximize revenue and market share by providing
profitable services such as invasive cardiac procedures, even if
they duplicate those of neighboring hospitals and preclude
cooperation.
A large health maintenance organization may need to
contract with outside hospitals to provide primary angioplasty
services and would most likely face higher charges for primary
angioplasty than the optimal cost of ;$2,000 in our base case,
possibly closer to the $5,000 cost in our “Add Needed Lab”
scenario. In addition, most patients with chest pain do not
actually have an acute myocardial infarction. If emergency
medical services triaged all patients with chest pain to regional
centers without attempting to select those with an acute
myocardial infarction, costs to a third-party payer could in-
crease even more. Thus, if regional triaging is considered, close
monitoring of actual costs and outcomes will be warranted to
avoid providing primary angioplasty in a cost-ineffective man-
ner.
Limitations of the study. In this study, primary angioplasty
did not result in long-term cost savings compared with no
intervention, in part because increased survivorship led to
higher costs of future lifetime medical care. Including these
costs presents the most accurate picture of a policy’s effects
(52). When future medical costs were not included, the costs/
QALY saved by primary angioplasty appeared to be 50% to
90% lower. Estimates from other studies, such as the $33,000/
life-year saved by t-PA versus streptokinase, usually have not
included such costs (53).
Although we did not include work-loss costs, this would not
have changed our conclusions because patients who undergo
primary angioplasty have at least equal and possibly better
cardiac functional status than those who receive thrombolysis
(4). This analysis used the wholesale price of t-PA, which may
be higher than the true cost to society of manufacturing the
medication. However, the results did not change when the
lower price of streptokinase was used. New thrombolytic
agents or other technologies under development may have
lower stroke rates or superior effectiveness than t-PA, but this
analysis showed that primary angioplasty would be cost-
effective relative to thrombolysis even without any advantage
in stroke rates.
Conclusions. Primary angioplasty for patients with an
acute myocardial infarction is likely to be cost-effective at
hospitals that already have fully supported cardiac catheteriza-
tion laboratories operating at high volumes. The procedure’s
relative cost-ineffectiveness at low volumes supports regional-
ization of cardiac services in urban areas. However, if primary
angioplasty services are to be effectively regionalized in the
United States, creative approaches to overcoming competitive
barriers and close monitoring of outcomes and costs will be
needed.
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Figure 2. Cost/QALY saved by using a policy
of primary angioplasty, depending on proce-
dure volume (based on the number of acute
myocardial infarctions/year at the admitting
hospital). Solid lines 5 cost/QALY saved
under the three alternative hospital scenarios
given base case (efficacy) assumptions about
health outcomes; dashed lines 5 cost/QALY
saved under the three alternative hospital
scenarios, given effectiveness assumptions es-
timated from community-based observational
trials; solid symbols 5 analyses where pri-
mary angioplasty is compared with thrombol-
ysis; open symbols 5 analyses where primary
angioplasty had dominance or extended dom-
inance over thrombolysis and is thus com-
pared with no intervention. When volume is
varied, assumptions about health outcomes
are not changed, except as depicted using the
dashed lines for effectiveness assumptions.
The cost/QALY saved by primary angioplasty
under the base case hospital (“Fully Covered
Lab” scenario) was not depicted and re-
mained at $12,000 compared with no inter-
vention under both efficacy and effectiveness
assumptions regardless of volume. Using low
volumes and effectiveness assumptions about
health outcomes, the cost/QALY saved was
.$100,000 under most hospital scenarios.
1748 LIEU ET AL. JACC Vol. 30, No. 7
PRIMARY ANGIOPLASTY COST-EFFECTIVENESS December 1997:1741–50
through the Coronary Heart Disease Policy Model. We thank Thomas Thom,
PhD for advice on calculation of the nursing home costs of stroke survivors and
Menko Jan deBoer, MD and Felix Zjilstra, MD, who shared advance data on
cardiac functional status after primary angioplasty. We thank Michael Sorel,
MPH, who initiated the programming and analysis, and many others with Kaiser
Permanente, including Laura Finkler, MPH, Gary Salyer, MDiv, Lyn Wender,
Marie Miller, PhD, John Mosher, MBA, Agnes Cronin, MBA and Matt Kaplan,
MBA. We are indebted to Dr. Reeder and to Joe Selby, MD for thoughtful
reviews of the manuscript and to Jay Crosson, MD for sponsoring the study.
References
1. Grines CL, Brown KF, Marco J, et al. A comparison of immediate
angioplasty with thrombolytic therapy for acute myocardial infarction.
N Engl J Med 1993;328:673–9.
2. Gibbons RJ, Holmes DR, Reeder GS, Bailey KR, Hopfenspirger MR, Gersh
BJ. Immediate angioplasty compared with the administration of a thrombo-
lytic agent followed by conservative treatment for myocardial infarction.
N Engl J Med 1993;328:685–91.
3. Reeder GS, Bailey KR, Gersh BJ, Holmes DR, Christianson J, Gibbons RJ.
Cost comparison of immediate angioplasty versus thrombolysis followed by
conservative therapy for acute myocardial infarction: a randomized prospec-
tive trial. Mayo Clin Proc 1994;69:5–12.
4. de Boer MJ, van Hout BA, Liem AL, Suryapranata H, Hoorntje JCA,
Zijlstra F. Cost-effectiveness analysis of primary coronary angioplasty vs.
thrombolysis for acute myocardial infarction. Am J Cardiol 1995;76:830–3.
5. Stone GW, Grines CL, Rothbaum D, et al. Analysis of the relative costs and
effectiveness of primary angioplasty versus tissue-type plasminogen activator:
the Primary Angioplasty in Myocardial Infarction (PAMI) trial. J Am Coll
Cardiol 1997;29:901–7.
6. Every NR, Parson LS, Hlatky M, Martin JS, Weaver WD. A comparison of
thrombolytic therapy with primary coronary angioplasty for acute myocardial
infarction. N Engl J Med 1996;335:1253–60.
7. Rogers WJ, Dean LS, Moore PB, et al. Comparison of primary angioplasty
versus thrombolytic therapy for acute myocardial infarction. Am J Cardiol
1994;74:111–8.
8. Ritchie JL, Phillips KA, Luft HS. Coronary angioplasty: statewide experi-
ence in California. Circulation 1993;88:2735–43.
9. Jollis JG, Peterson ED, DeLong ER, et al. The relation between the volume
of coronary angioplasty procedures at hospitals treating Medicare beneficia-
ries and short-term mortality. N Engl J Med 1994;331:1625–9.
10. Kimmel SE, Berlin JA, Laskey WK. The relationship between coronary
angioplasty procedure volume and major complications. JAMA 1995;274:
1137–42.
11. Lieu TA, Lundstrom RJ, Ray GT, Fireman BH, Gurley RJ, Parmley WW.
The initial cost of primary angioplasty for acute myocardial infarction. J Am
Coll Cardiol 1996;28:882–9.
12. Weaver WD, Litwin PE, Martin JS, et al. Use of direct angioplasty for
treatment of patients with acute myocardial infarction in hospitals with and
without on-site cardiac surgery. Circulation 1993;88:2067–75.
13. Goldman L. Cost and quality of life: thrombolysis and primary angioplasty.
J Am Coll Cardiol 1995;25 Suppl:38S–41S.
14. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico
(GISSI). GISSI-2: a factorial randomised trial of alteplase versus streptoki-
nase and heparin versus no heparin among 12,490 patients with acute
myocardial infarction. Lancet 1990;336:65–71.
15. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase,
oral aspirin, both, or neither among 17,187 cases of suspected acute
myocardial infarction: ISIS-2. Lancet 1988;335:349–60.
16. Graves EJ. Summary: National Hospital Discharge Survey. Advance data
from Vital and Health Statistics, No. 264. Hyattsville (MD): National Center
for Health Statistics, 1995.
17. McClellan M, McNeill BJ, Newhouse JP. Does more intensive treatment of
acute myocardial infarction in the elderly reduce mortality? Analysis using
instrumental variables. JAMA 1994;272:859–66.
18. Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman
L. Forecasting coronary heart disease incidence, mortality, and cost: the
Coronary Heart Disease Policy Model. Am J Public Health 1987;77:1417–26.
19. Lieu TA, Gurley RJ, Lundstrom RJ, Parmley WW. Primary angioplasty and
thrombolysis for acute myocardial infarction: an evidence summary. J Am
Coll Cardiol 1996;27:737–50.
20. Krumholz HM, Friesinger GC, Cook EF, Lee TH, Rouan GW, Goldman L.
Relationship of age with eligibility for thrombolytic therapy and mortality
among patients with suspected acute myocardial infarction. J Am Geriatr
Soc 1994;42:127–31.
21. Althouse R, Maynard C, Cerqueira MD, Olsufka M, Ritchie JL, Kennedy
JW. The Western Washington myocardial infarction registry and emergency
department tissue plasminogen activator treatment trial. Am J Cardiol
1990;66:1298–303.
22. The TIMI Study Group. Comparison of invasive and conservative strategies
after treatment with intravenous tissue plasminogen activator in acute
myocardial infarction. N Engl J Med 1989;320:618–27.
23. Hibbard MD, Holmes DRJ, Bailey KR, et al. Percutaneous transluminal
coronary angioplasty in patients with cardiogenic shock. J Am Coll Cardiol
1992;19:639–46.
24. Gacioch GM, Ellis SG, Lee L, et al. Cardiogenic shock complicating acute
myocardial infarction: the use of coronary angioplasty and the integration of
the new support devices into patient management. J Am Coll Cardiol
1992;19:647–53.
25. Yamamoto H, Hayashi Y, Oka Y, et al. Efficacy of percutaneous translumi-
nal coronary angioplasty in patients with acute myocardial infarction com-
plicated by cardiogenic shock. Jpn Circ J 1992;56:815–21.
26. Lee L, Bates ER, Pitt B, Walton JA, Laufer N, O’Neill WW. Percutaneous
transluminal coronary angioplasty improves survival in acute myocardial
infarction complicated by cardiogenic shock. Circulation 1988;78:1345–51.
27. Lee L, Erbel R, Brown TM, et al. Multicenter registry of angioplasty therapy
of cardiogenic shock: initial and long-term survival. J Am Coll Cardiol
1991;17:599–603.
28. Brodie BR, Weintraub RA, Stuckey TD, et al. Outcomes of direct coronary
angioplasty for acute myocardial infarction in candidates and non-candidates
for thrombolytic therapy. Am J Cardiol 1991;67:7–12.
29. Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care
unit. Am J Cardiol 1967;20:457–64.
30. Scheidt S, Ascheim R, Killip T. Shock after acute myocardial infarction: a
clinical and hemodynamic profile. Am J Cardiol 1970;26:556–64.
31. Cragg DR, Friedman HZ, Bonema JD, et al. Outcome of patients with acute
myocardial infarction who are ineligible for thrombolytic therapy. Ann
Intern Med 1991;115:173–7.
32. Himbert D, Juliard J-M, Steg G, et al. Primary coronary angioplasty for
acute myocardial infarction with contraindication to thrombolysis. Am J
Cardiol 1993;71:377–81.
33. The GUSTO Angiographic Investigators. The effects of tissue plasminogen
activator, streptokinase, or both on coronary-artery patency, ventricular
function, and survival after acute myocardial infarction. N Engl J Med
1993;329:1615–22.
34. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico.
GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and
together on 6-week mortality and ventricular function after acute myocardial
infarction. Lancet 1994;343:1115–22.
35. ISIS-4 Collaborative Group. ISIS-4: a randomised factorial trial assessing
early oral captopril, oral mononitrate, and intravenous magnesium sulphate
in 58,050 patients with suspected acute myocardial infarction. Lancet
1995;345:669–85.
36. Michels KB, Yusuf S. Does PTCA in acute myocardial infarction affect
mortality and reinfarction rates? A quantitative overview (meta-analysis) of
the randomized clinical trials. Circulation 1995;91:476–85.
37. Zijlstra F, de Boer MJ, Hoorntje JCA, Reiffers S, Reiber JHC, Suryapranata
H. A comparison of immediate coronary angioplasty with intravenous
streptokinase in acute myocardial infarction. N Engl J Med 1993;328:680–4.
38. Ribeiro EE, Silva LA, Carneiro R, et al. Randomized trial of direct coronary
angioplasty versus intravenous streptokinase in acute myocardial infarction.
J Am Coll Cardiol 1993;22:376–80.
39. Simari RD, Berger PB, Bell MR, Gibbons RJ, Holmes DR. Coronary
angioplasty in acute myocardial infarction: primary, immediate adjunctive,
rescue, or deferred adjunctive approach? Mayo Clin Proc 1994;69:346–58.
40. Nunn C, O’Neill W, Rothbaum D, et al. Primary angioplasty for myocardial
infarction improves long-term survival: PAMI-1 follow-up [abstract]. J Am
Coll Cardiol 1996;25 Suppl:153A.
41. Goldberg RJ, Gore JM, Alpert J, et al. Cardiogenic shock after acute
myocardial infarction. Incidence and mortality from a community-wide
perspective, 1975 to 1988. N Engl J Med 1991;325:1117–22.
1749JACC Vol. 30, No. 7 LIEU ET AL.
December 1997:1741–50 PRIMARY ANGIOPLASTY COST-EFFECTIVENESS
42. Hunink MG, Goldman L, Tosteson AN. The recent decline in mortality from
coronary heart disease, 1980–1990: the effect of secular trends in risk factors
and treatment. JAMA 1997;277:535–42.
43. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-Effectiveness
in Health and Medicine. New York: Oxford University Press, 1996.
44. Nease RJ, Kneeland T, O’Connor GT, et al. Variation in patient utilities for
outcomes of the management of chronic stable angina. JAMA 1995;273:
1185–90.
45. Solomon NA, Glick HA, Russo CJ, et al. Patient preferences for stroke
outcomes. Stroke 1994;25:1721–5.
46. Krumholz HM, Pasternak RC, Weinstein MC, et al. Cost effectiveness of
thrombolytic therapy with streptokinase in elderly patients with suspected
acute myocardial infarction. N Engl J Med 1992;327:7–13.
47. National Center for Health Statistics. The National Nursing Home Survey
DHHS Publication No. (PHS) 89-1758. Hyattsville (MD): U.S. Department
of Health and Human Services, 1989.
48. National Center for Health Statistics. Health United States 1994. Hyattsville
(MD): U.S. Department of Health and Human Services, 1995.
49. Hahn B, Lefkowitz D. Annual expenses and sources of payment for health
care services (AHCPR Pub. No. 93-0007). National Medical Expenditure
Survey Research Findings 14, Agency for Health Care Policy and Research.
Rockville, MD: Public Health Service, 1992.
50. Newby LK, Rutsch WR, Califf RM, et al. Time from symptom onset to
treatment and outcomes after thrombolytic therapy. J Am Coll Cardiol
1996;27:1646–55.
51. Boersma E, Maas ACP, Deckers JW, Simoons ML. Early thrombolytic
treatment in acute myocardial infarction: reappraisal of the golden hour.
Lancet 1996;348:771–5.
52. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis.
J Health Econ 1996. In press.
53. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic
therapy with tissue plasmogen activator as compared with streptokinase for
acute myocardial infarction. N Engl J Med 1995;332:1418–24.
54. The Thrombolysis Early in Acute Heart Attack Trial Study Group. Very
early thrombolytic therapy in suspected acute myocardial infarction. Am J
Cardiol 1990;65:401–7.
55. Kennedy JW, Martin GV, Davis KB, et al. The Western Washington
intravenous streptokinase in acute myocardial infarction randomized trial.
Circulation 1988;77:345–52.
56. Simoons ML, Serruys PW, VanDenBrand M, et al. Early thrombosis in acute
myocardial infarction: limitation of infarct size and improved survival. J Am
Coll Cardiol 1986;7:717–28.
57. ISIS Pilot Study Investigators. Randomized factorial trial of high-dose
intravenous streptokinase, of oral aspirin and of intravenous heparin in acute
myocardial infarction. Eur Heart J 1987;8:634–42.
58. Cerqueira MD, Maynard C, Ritchie JL, Davis KB, Kennedy JW. Long-term
survival in 618 patients from the Western Washington Streptokinase in
Myocardial Infarction trials. J Am Coll Cardiol 1992;20:1452–9.
59. Arnold AER, Simoons ML, Van de Werf F, et al. Recombinant tissue-type
plasminogen activator and immediate angioplasty in acute myocardial in-
farction: one-year follow-up. Circulation 1992;86:111–20.
60. AIMS Trial Study Group. Long-term effects of intravenous anistreplase in
acute myocardial infarction: final report of the AIMS study. Lancet 1990;
335:427–31.
61. Simoons ML, Vos J, Tijssen JGP, et al. Long-term benefit of early
thrombolytic therapy in patients with acute myocardial infarction: 5 year
follow-up of a trial conducted by the Interuniversity Cardiology Institute of
the Netherlands. J Am Coll Cardiol 1989;14:1609–15.
62. Califf RM, Topol EJ, George BS, et al. One-year outcome after therapy with
tissue plasminogen activator: report from the Thrombolysis and Angioplasty
in Myocardial Infarction trial. Am Heart J 1990;199:777–85.
63. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton
JR. Effects of alteplase in acute myocardial infarction: 6-month results from
the ASSET study. Lancet 1990;335:1175–8.
64. O’Murchu B, Gersh BJ, Reeder GS, Bailey KR, Holmes DR. Late outcome
after percutaneous transluminal coronary angioplasty during acute myocar-
dial infarction. Am J Cardiol 1993;72:634–9.
65. Terrin ML, Williams DO, Kleiman NS, et al. Two- and three-year results of
the Thrombolysis in Myocardial Infarction (TIMI) Phase II clinical trial.
J Am Coll Cardiol 1993;22:1763–72.
66. Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico
(GISSI). Long-term effects of intravenous thrombolysis in acute myocardial
infarction: final report of the GISSI study. Lancet 1987;2:871–4.
67. Mori T, Nosaka H, Kimura T, Nobuyoshi M. Long-term follow-up of patients
treated with intracoronary thrombolysis or percutaneous transluminal coronary
angioplasty for acute myocardial infarction. J Cardiol 1991;21:323–36.
68. Anonymous. 1993 Drug Topics Red Book. Montvale (NJ): Medical Eco-
nomics Data, 1993.
1750 LIEU ET AL. JACC Vol. 30, No. 7
PRIMARY ANGIOPLASTY COST-EFFECTIVENESS December 1997:1741–50
